htasurv: a Stata module for performing survival analysis in economic evaluations

Jan 2, 2017

Written by David Trueman, Director

htasurv is an open source Stata module for assessing alternative parametric distributions when extrapolating survival data for use in health economic models. The function distfind loops through alternative distributions (specified by the user) and reports statistics and produces plots specified in NICE DSU TSD 14.0. The function distanalysis writes out results and useful statistics (e.g. the variance-covariance matrix) for the analyst. The module can be installed directly from github, using the github module. Once the github module is installed, installation of htasurv is:

github install sourceHEOR/htasurv

Syntax
For distfind:

distfind [varlist], dlist(string) timevar(varname) failure(varname) [GRaphs]

Where varlist are the variables in the survival model (often treatment), timevar is the variable defining the time-to-event, and failure is a binary variable for failure vs censoring (1=failure, 0=censored). If the graphs option is used, plots will be saved to curentdirectory/graphs. dlist is the list of distributions to estimate as lowercase strings (see example below). For distanalysis:

distanalysis [varlist], sdist(string) doctitle(string) [caption(string)] [fname(string)]

distanalysis will estimate the model with variables given in varlist with distribution given in sdist (full title; all lowercase). The resulting model will be written to .csv and .rtf files with file names given by doctitle. If a folder location is specified by fname, all files will be stored there (otherwise, the current directory is used).

Example use

sysuse cancer.dta, clear

global dlist “gamma weibull gompertz exponential lognormal loglogistic”

distfind age i.drug, dlist($dlist) timevar(studytime) failure(died)

distanalysis age i.drug, sdist(gompertz) doctitle(test) caption(“Gompertz”)

The software can be downloaded here. This software is released under the GNU General Public License version 3.


More Insights

Accelerating hope? Optimising rare disease MHRA/FDA approval pathways and access strategy considerations

Accelerating hope? Optimising rare disease MHRA/FDA approval pathways and access strategy considerations

Written by Jo Wallis, Head of Commercialisation and Pricing Strategy   The recent developments put forward by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Food and Drug Administration (FDA) to streamline the ... Read more

The role of orphan drug designations in driving research and innovation for rare diseases

The role of orphan drug designations in driving research and innovation for rare diseases

Written by Emma Bartram, Associate Systematic Review Analyst   A rare disease is one that affects fewer than 1 in 2,000 individuals, and yet 3.5–5.9% of people will experience a rare disease over the course of their lifetime (1,2). ... Read more

HTA monthly update

HTA monthly update

By Toby Hobbs   Changes to NICE ICER thresholds confirmed NICE has announced that from April 2026 there will be an increase to its cost-effectiveness threshold. This marks one of the biggest shifts in UK Health technology assessment ... Read more

Evaluating Health Inequalities: NICE’s Modular Update

Evaluating Health Inequalities: NICE’s Modular Update

Written by Paloma Charlesworth (Assistant Project Manager)   Background  Health inequalities are systematic, avoidable, and unjust differences in health outcomes between patient groups. Despite decades of policy and research, they not ... Read more